Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

v3.24.1.1.u2
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Purchase of Arbuz shares
Purchase of ReKassa shares
Common Stock
Additional paid in capital
Retained earnings
Retained earnings
Purchase of Arbuz shares
Retained earnings
Purchase of ReKassa shares
Accumulated other comprehensive loss
Total equity attributable to the shareholders'
Total equity attributable to the shareholders'
Purchase of Arbuz shares
Total equity attributable to the shareholders'
Purchase of ReKassa shares
Non-controlling interest
Non-controlling interest
Purchase of Arbuz shares
Non-controlling interest
Purchase of ReKassa shares
Shares issued, beginning of period (in shares) at Mar. 31, 2021       58,443,212,000                      
Equity, beginning of period at Mar. 31, 2021 $ 307,674     $ 58 $ 135,260 $ 214,430     $ (40,433) $ 309,315     $ (1,641)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation (in shares)       1,039,000,000                      
Stock based compensation 15,746     $ 1 15,745         15,746          
Capital contribution 24,417       24,417         24,417          
Exercise of options (in shares)       60,000,000                      
Exercise of options 119       119         119          
Sale of Freedom UA shares 416       (796)         (796)     1,212    
Other comprehensive loss (2,070)               (2,070) (2,070)          
Foreign currency translation adjustments, net of tax effect (20,622)               (20,622) (20,622)          
Net income $ 220,928         227,494       227,494     (6,566)    
Shares issued, end of period (in shares) at Mar. 31, 2022 59,542,212     59,542,212,000                      
Equity, end of period at Mar. 31, 2022 $ 546,608     $ 59 174,745 441,924     (63,125) 553,603     (6,995)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation (in shares)       57,216,000                      
Stock based compensation 11,038       11,038         11,038          
Capital contribution 677       677         677          
Exercise of options (in shares)       59,763,000                      
Issuance of shares of common stock 4,290       4,290         4,290          
Acquisition of insurance companies (26,588)       (26,588)         (26,588)          
Reclassification of loss from cumulative translation adjustment of discontinued operations 25,415               25,415 25,415          
Other comprehensive loss (1,485)               (1,485) (1,485)          
Foreign currency translation adjustments, net of tax effect 5,195               5,195 5,195          
Net income $ 205,586         205,140       205,140     446    
Shares issued, end of period (in shares) at Mar. 31, 2023 59,659,191     59,659,191,000                      
Equity, end of period at Mar. 31, 2023 $ 770,736     $ 59 164,162 647,064     (34,000) 777,285     (6,549)    
Equity, end of period (Cumulative adjustment from adoption of ASC 326) at Mar. 31, 2023 (22,772)         (22,772)       (22,772)          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Stock based compensation (in shares)       662,622,000                      
Stock based compensation 19,627     $ 1 19,626         19,627          
Disposal of FF Ukraine 0         (6,549)       (6,549)     6,549    
Purchase of subsidiary shares   $ 9,097 $ 256       $ 5,457 $ 0     $ 5,457 $ 0   $ 3,640 $ 256
Other comprehensive loss 2,987               2,987 2,987          
Foreign currency translation adjustments, net of tax effect 12,075               12,075 12,075          
Net income $ 374,952         375,540       375,540     (588)    
Shares issued, end of period (in shares) at Mar. 31, 2024 60,321,813     60,321,813,000                      
Equity, end of period at Mar. 31, 2024 $ 1,166,958     $ 60 $ 183,788 $ 998,740     $ (18,938) $ 1,163,650     $ 3,308